170 related articles for article (PubMed ID: 28340541)
1. Drug Discovery Testing Compounds in Patient Samples by Automated Flow Cytometry.
Hernández P; Gorrochategui J; Primo D; Robles A; Rojas JL; Espinosa AB; Gómez C; Martínez-López J; Bennett TA; Ballesteros J
SLAS Technol; 2017 Jun; 22(3):325-337. PubMed ID: 28340541
[TBL] [Abstract][Full Text] [Related]
2. Ex-vivo drug testing predicts chemosensitivity in acute myeloid leukemia.
Lin L; Tong Y; Straube J; Zhao J; Gao Y; Bai P; Li J; Wang J; Wang H; Wang X; Huang S; Xu W; Song X; Li L
J Leukoc Biol; 2020 May; 107(5):859-870. PubMed ID: 32293060
[TBL] [Abstract][Full Text] [Related]
3. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
Daher A; de Groot J
Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
[TBL] [Abstract][Full Text] [Related]
4. Predictive Value of Ex Vivo Chemosensitivity Assays for Individualized Cancer Chemotherapy: A Meta-Analysis.
Blom K; Nygren P; Larsson R; Andersson CR
SLAS Technol; 2017 Jun; 22(3):306-314. PubMed ID: 28378608
[TBL] [Abstract][Full Text] [Related]
5. The AutoDiSC: development and validation of a novel chemotherapy sensitivity and resistance assay.
Schinköthe T; Thiruchittampalam D; Schmidt A; Bomholt N; Staib P
Anticancer Res; 2013 Jun; 33(6):2491-8. PubMed ID: 23749900
[TBL] [Abstract][Full Text] [Related]
6. Culture and Drug Profiling of Patient Derived Malignant Pleural Effusions for Personalized Cancer Medicine.
Ruiz C; Kustermann S; Pietilae E; Vlajnic T; Baschiera B; Arabi L; Lorber T; Oeggerli M; Savic S; Obermann E; Singer T; Rothschild SI; Zippelius A; Roth AB; Bubendorf L
PLoS One; 2016; 11(8):e0160807. PubMed ID: 27548442
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine.
Bennett TA; Montesinos P; Moscardo F; Martinez-Cuadron D; Martinez J; Sierra J; García R; de Oteyza JP; Fernandez P; Serrano J; Fernandez A; Herrera P; Gonzalez A; Bethancourt C; Rodriguez-Macias G; Alonso A; Vera JA; Navas B; Lavilla E; Lopez JA; Jimenez S; Simiele A; Vidriales B; Gonzalez BJ; Burgaleta C; Hernandez Rivas JA; Mascuñano RC; Bautista G; Perez Simon JA; Fuente Ade L; Rayón C; Troconiz IF; Janda A; Bosanquet AG; Hernandez-Campo P; Primo D; Lopez R; Liebana B; Rojas JL; Gorrochategui J; Sanz MA; Ballesteros J
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):305-18. PubMed ID: 24468131
[TBL] [Abstract][Full Text] [Related]
8. Precision Cancer Medicine in the Acoustic Dispensing Era: Ex Vivo Primary Cell Drug Sensitivity Testing.
Kulesskiy E; Saarela J; Turunen L; Wennerberg K
J Lab Autom; 2016 Feb; 21(1):27-36. PubMed ID: 26721820
[TBL] [Abstract][Full Text] [Related]
9. Personalized in vitro cancer models to predict therapeutic response: Challenges and a framework for improvement.
Morgan MM; Johnson BP; Livingston MK; Schuler LA; Alarid ET; Sung KE; Beebe DJ
Pharmacol Ther; 2016 Sep; 165():79-92. PubMed ID: 27218886
[TBL] [Abstract][Full Text] [Related]
10. 3D Culture as a Clinically Relevant Model for Personalized Medicine.
Fong ELS; Toh TB; Yu H; Chow EK
SLAS Technol; 2017 Jun; 22(3):245-253. PubMed ID: 28277923
[TBL] [Abstract][Full Text] [Related]
11. Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery.
Powley IR; Patel M; Miles G; Pringle H; Howells L; Thomas A; Kettleborough C; Bryans J; Hammonds T; MacFarlane M; Pritchard C
Br J Cancer; 2020 Mar; 122(6):735-744. PubMed ID: 31894140
[TBL] [Abstract][Full Text] [Related]
12. Large-Scale Drug Screens Support Precision Medicine.
Gray JW; Mills GB
Cancer Discov; 2015 Nov; 5(11):1130-2. PubMed ID: 26526695
[TBL] [Abstract][Full Text] [Related]
13. Multitask learning improves prediction of cancer drug sensitivity.
Yuan H; Paskov I; Paskov H; González AJ; Leslie CS
Sci Rep; 2016 Aug; 6():31619. PubMed ID: 27550087
[TBL] [Abstract][Full Text] [Related]
14. Automation of a phospho-STAT5 staining procedure for flow cytometry for application in drug discovery.
Malergue F; van Agthoven A; Scifo C; Egan D; Strous GJ
J Biomol Screen; 2015 Mar; 20(3):416-21. PubMed ID: 25325258
[TBL] [Abstract][Full Text] [Related]
15. Dielectrophoretic analysis of treated cancer cells for rapid assessment of treatment efficacy.
Mahabadi S; Labeed FH; Hughes MP
Electrophoresis; 2018 Apr; 39(8):1104-1110. PubMed ID: 29405335
[TBL] [Abstract][Full Text] [Related]
16. Development of the Histoculture Drug Response Assay (HDRA).
Hoffman RM; Vescio RA
Methods Mol Biol; 2018; 1760():39-48. PubMed ID: 29572792
[TBL] [Abstract][Full Text] [Related]
17. In vitro evaluation of new anticancer drugs, exemplified by vinorelbine, using the fluorometric microculture cytotoxicity assay on human tumor cell lines and patient biopsy cells.
Fridborg H; Nygren P; Dhar S; Csoka K; Kristensen J; Larsson R
J Exp Ther Oncol; 1996 Sep; 1(5):286-95. PubMed ID: 9414416
[TBL] [Abstract][Full Text] [Related]
18. Sensor-based cell and tissue screening for personalized cancer chemotherapy.
Kleinhans R; Brischwein M; Wang P; Becker B; Demmel F; Schwarzenberger T; Zottmann M; Wolf P; Niendorf A; Wolf B
Med Biol Eng Comput; 2012 Feb; 50(2):117-26. PubMed ID: 22290601
[TBL] [Abstract][Full Text] [Related]
19. Micro-dissected tumor tissues on chip: an ex vivo method for drug testing and personalized therapy.
Astolfi M; Péant B; Lateef MA; Rousset N; Kendall-Dupont J; Carmona E; Monet F; Saad F; Provencher D; Mes-Masson AM; Gervais T
Lab Chip; 2016 Jan; 16(2):312-25. PubMed ID: 26659477
[TBL] [Abstract][Full Text] [Related]
20. Robust scoring of selective drug responses for patient-tailored therapy selection.
Chen Y; He L; Ianevski A; Ayuda-Durán P; Potdar S; Saarela J; Miettinen JJ; Kytölä S; Miettinen S; Manninen M; Heckman CA; Enserink JM; Wennerberg K; Aittokallio T
Nat Protoc; 2024 Jan; 19(1):60-82. PubMed ID: 37996540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
